Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ. Reardon DA, et al. Among authors: conway as. Cancer Immunol Res. 2016 Feb;4(2):124-35. doi: 10.1158/2326-6066.CIR-15-0151. Epub 2015 Nov 6. Cancer Immunol Res. 2016. PMID: 26546453
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.
Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, Klebanov B, Landesman Y, Kauffman M, Shacham S, Kung AL, Wang JC, Letai A, Look AT. Etchin J, et al. Among authors: conway as. Leukemia. 2016 Jan;30(1):190-9. doi: 10.1038/leu.2015.194. Epub 2015 Jul 23. Leukemia. 2016. PMID: 26202935 Free PMC article.
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
Pikman Y, Alexe G, Roti G, Conway AS, Furman A, Lee ES, Place AE, Kim S, Saran C, Modiste R, Weinstock DM, Harris M, Kung AL, Silverman LB, Stegmaier K. Pikman Y, et al. Among authors: conway as. Clin Cancer Res. 2017 Feb 15;23(4):1012-1024. doi: 10.1158/1078-0432.CCR-15-2869. Epub 2016 Nov 9. Clin Cancer Res. 2017. PMID: 28151717 Free PMC article.
A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
Guenther LM, Dharia NV, Ross L, Conway A, Robichaud AL, Catlett JL 2nd, Wechsler CS, Frank ES, Goodale A, Church AJ, Tseng YY, Guha R, McKnight CG, Janeway KA, Boehm JS, Mora J, Davis MI, Alexe G, Piccioni F, Stegmaier K. Guenther LM, et al. Clin Cancer Res. 2019 Feb 15;25(4):1343-1357. doi: 10.1158/1078-0432.CCR-18-0372. Epub 2018 Nov 5. Clin Cancer Res. 2019. PMID: 30397176 Free PMC article.
Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer.
Malone CF, Dharia NV, Kugener G, Forman AB, Rothberg MV, Abdusamad M, Gonzalez A, Kuljanin M, Robichaud AL, Conway AS, Dempster JM, Paolella BR, Dumont N, Hovestadt V, Mancias JD, Younger ST, Root DE, Golub TR, Vazquez F, Stegmaier K. Malone CF, et al. Among authors: conway as. Cancer Discov. 2021 Sep;11(9):2282-2299. doi: 10.1158/2159-8290.CD-20-1213. Epub 2021 Apr 21. Cancer Discov. 2021. PMID: 33883167 Free PMC article.
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
Mabe NW, Huang M, Dalton GN, Alexe G, Schaefer DA, Geraghty AC, Robichaud AL, Conway AS, Khalid D, Mader MM, Belk JA, Ross KN, Sheffer M, Linde MH, Ly N, Yao W, Rotiroti MC, Smith BAH, Wernig M, Bertozzi CR, Monje M, Mitsiades CS, Majeti R, Satpathy AT, Stegmaier K, Majzner RG. Mabe NW, et al. Among authors: conway as. Nat Cancer. 2022 Aug;3(8):976-993. doi: 10.1038/s43018-022-00405-x. Epub 2022 Jul 11. Nat Cancer. 2022. PMID: 35817829 Free PMC article.
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling.
Iniguez AB, Alexe G, Wang EJ, Roti G, Patel S, Chen L, Kitara S, Conway A, Robichaud AL, Stolte B, Bandopadhayay P, Goodale A, Pantel S, Lee Y, Cheff DM, Hall MD, Guha R, Davis MI, Menard M, Nasholm N, Weiss WA, Qi J, Beroukhim R, Piccioni F, Johannessen C, Stegmaier K. Iniguez AB, et al. Cancer Cell. 2018 Dec 10;34(6):922-938.e7. doi: 10.1016/j.ccell.2018.11.005. Cancer Cell. 2018. PMID: 30537514 Free PMC article.
An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML.
Lin S, Larrue C, Scheidegger NK, Seong BKA, Dharia NV, Kuljanin M, Wechsler CS, Kugener G, Robichaud AL, Conway AS, Mashaka T, Mouche S, Adane B, Ryan JA, Mancias JD, Younger ST, Piccioni F, Lee LH, Wunderlich M, Letai A, Tamburini J, Stegmaier K. Lin S, et al. Among authors: conway as. Cancer Discov. 2022 Feb;12(2):432-449. doi: 10.1158/2159-8290.CD-20-1851. Epub 2021 Sep 16. Cancer Discov. 2022. PMID: 34531254 Free PMC article.
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, Senapedis W, Landesman Y, Kauffman M, Shacham S, Wang JC, Look AT. Etchin J, et al. Among authors: conway as. Leukemia. 2017 Jan;31(1):143-150. doi: 10.1038/leu.2016.145. Epub 2016 May 23. Leukemia. 2017. PMID: 27211268 Free PMC article.
28 results